Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Based on surveys conducted in 2015 and 2018, the number appears to have nearly tripled in San Francisco.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
Molnupiravir, first developed for hepatitis C, might be able to prevent or treat COVID-19 outside of a clinical setting.
Among people treated for hepatitis C, diabetes and chronic kidney disease were both linked to a higher risk of cardiovascular death.
Regular exercise reduced liver fat accumulation and lowered liver stiffness.
Older age and injection drug use history were linked to higher hepatitis C positivity.
Inadequate access to healthy food was also associated with a higher chance of developing liver fibrosis.
Weight-loss surgery especially reduced obesity-related cancers in people with liver cirrhosis.
Nearly two-thirds of COVID-19 hospitalizations in the U.S. could be attributed to obesity, diabetes, hypertension, and heart failure.
One in five counties had an increase in deaths from hepatitis C, even as the nation experienced a general decline in mortality rates.
The risk was around 1.5 times higher for cancers of the breast and lungs and the gastrointestinal, gynecological and urinary systems.
Natural immunity and vaccine responses may be weaker in people with immune suppression, so they should get their second dose promptly.
Increased HCV testing and treatment for both HIV-positive and HIV-negative gay and bi men could help eliminate hep C.
Current screening guidelines may shortchange Black individuals.
Though usually safe, pregnant women who had liver transplants have a higher risk of some maternal and fetal complications.
People who were exposed to smoke during both childhood and adulthood were at greater risk.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.